Diadem DX
Drug Discovery
1backers · CDP Venture Capital
$2.5Mgrants · 1 grant · CORDIS
50+team · employees, estimated range
11stories in the press
Overview
"There is still no cheap and effective way to diagnose the disease...". – Voices of Alzheimer’s disease – Alzheimer’s association, 2008.
Funding and backers
Team
51-200
employees, estimated range
Grants
$2.5M
1 grant · CORDIS
Backers
1
CDP Venture Capital
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 1, 2022
Won a grant $2.5M · CORDIS
Tractionpublic signals, read monthly
Web presence
top 6%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Sep 2022 | $2.5M | — | CORDIS |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
What's AltPep?. We are a group of innovators working to transform the diagnosis and treatment of amyloid diseases, enabling action earlier…
Babylon is a drug development company pursuing a transformational treatment for Alzheimer’s. Meet our team and explore how we discover…
We are bringing more disease-causing targets within the reach of small molecule therapeutics to transform care for patients with…
Treeline Biosciences is a biotechnology company developing small-molecule medicines for cancer and immune diseases.
Applied Cognition is a platform therapeutic company developing drugs to enhance brain glymphatic function and treat Alzheimer’s disease.
Cognito is developing disease-modifying treatments to revive the health and well-being of patients living with Alzheimer’s.
Financials
Total raised
$2.5M
Latest round
Grant
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Grant | 2022 | $2.5M | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
CDP Venture CapitalVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Diadem awarded US patent for AlzoSure Alzheimer's disease prediction technology
Diadem awarded US patent for AlzoSure Alzheimer's disease prediction technology New patent extends protection for U-p53AZ biomarker detection methods ahead of planned commercial launch AlzoSure Predict will help clinicians assess the likelihood of progres
Read more
Report
Seed Healthcare Leads Strategic Investment in Diadem
Seed Healthcare Leads Strategic Investment in Diadem Partnership supports U.S. commercialization of Diadem's blood-based Alzheimer's diagnostic technology MIAMI, FL and MILAN, Italy, August 13 2026 Seed Healthcare today announced it has led a strategic in
Read more
Report
Diadem Unveils Novel Findings on Early Alzheimer's Disease Detection Using p53-Specific Antibody at CTAD 2024
Diadem Unveils Novel Findings on Early Alzheimer's Disease Detection Using p53-Specific Antibody at CTAD 2024 Milano, Italy, November 1, 2024 - Diadem SpA, in partnership with researchers from the University of Texas Medical Branch, led by Prof. Rakez Kay
Read more
Report
Diadem Appoints Michael Rasche as Chief Executive Officer
Diadem Appoints Michael Rasche as Chief Executive Officer Brings International Perspective and Extensive Experience Across Multiple Life Sciences Sectors to Advance Diadem's Pioneering Prognostic Technology for the Early Detection of Alzheimer's Disease M
Read more
Report
Diadem SpA Announces Exclusive U.S. Licensing Agreement with Quest Diagnostics for Its AlzoSure Predict Alzheimer's Disease Prognostic Technology
Diadem SpA Announces Exclusive U.S. Licensing Agreement with Quest Diagnostics for Its AlzoSure Predict Alzheimer's Disease Prognostic Technology -Quest to Develop and Market a Lab-developed Test Based on the IP of AlzoSure Predict in the United States, E
Read more
Report
Understanding treatment pathways for Alzheimer's Disease
Understanding treatment pathways for Alzheimer's Disease In the realm of neurological disorders, Alzheimer's Disease (AD) stands as one of the most challenging and devastating conditions of our time. With its progressive nature and profound impact on memo
Read more
Report
Identification and management of Alzheimer's Disease (AD)Diadem Presents Data at 2023 AAIC Showing Its AlzoSure Blood Test Can Identify Patients at High Risk of Significant Cognitive Decline Due to Alzheimer's DiseaseIdentification and management of Alzheimer's Disease (AD)
Diadem Presents Data at 2023 AAIC Showing Its AlzoSure Blood Test Can Identify Patients at High Risk of Significant Cognitive Decline Due to Alzheimer's Disease -Data from 479-Patient Study Confirms Strong Prognostic Utility of AlzoSure Predict for Identi
Read more
Report
Identification and management of Alzheimer's Disease (AD)
Identification and management of Alzheimer's Disease (AD) Dementia is common, especially in the aging population. More than 55 million people, around the world live with dementia. Alzheimer's Disease (AD) is the most common form of dementia. In the united
Read more
Report
Diadem Reports New Data Showing Its AlzoSure Predict Blood Test Can Accurately Identify "Rapid Progressors" Who Will Develop Alzheimer's Disease Within Two Years
Diadem Reports New Data Showing Its AlzoSure Predict Blood Test Can Accurately Identify "Rapid Progressors" Who Will Develop Alzheimer's Disease Within Two Years -New Computational Approach with PPV 95% Represents Another Significant Feature of AlzoSure P
Read more
Report
At CTAD 2022 Diadem Highlights How Its AlzoSure Predict Prognostic Blood Test for Alzheimer's Disease Will Help Patients and Facilitate Development of New Therapies
At CTAD 2022 Diadem Highlights How Its AlzoSure Predict Prognostic Blood Test for Alzheimer's Disease Will Help Patients and Facilitate Development of New Therapies -Data Presented at CTAD Conference Shows that AlzoSure Predict Can Accurately Identify Sta
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Palo Alto
United States
HQ
50-200 est. staff